Nephroprotective Effect of Pentoxifylline Against Cisplatin in Patients With Head and Neck Cancer

Trial Title: Nephroprotective Effect of Pentoxifylline Against Cisplatin in Patients With Head and Neck Cancer

NCT ID: NCT05640817

Condition: Pentoxifylline, Cisplatin, Nephrotoxixcity

Conditions: Official terms:
Head and Neck Neoplasms
Pentoxifylline

Study type: Interventional

Study phase: N/A

Overall status: Unknown status

Study design:

Allocation: Randomized

Intervention model: Parallel Assignment

Primary purpose: Prevention

Masking: Single (Participant)

Intervention:

Intervention type: Drug
Intervention name: Pentoxifylline 400 mg SR tablets
Description: a nonspecific phosphodiesterase inhibitor, was first considered in the treatment of peripheral vascular diseases
Arm group label: Group two as Pentoxifylline

Intervention type: Drug
Intervention name: cisplatin with standard hydration with normal saline
Description: chemotherapy
Arm group label: Group 1 as control group

Summary: Head and neck squamous cell carcinoma (HNSCC) encompasses a variety of tumors originating in the lip, oral cavity, hypopharynx, oropharynx, nasopharynx and larynx. It is the sixth most common malignancy worldwide accounting for approximately 6% of all cancer cases (Rettig and D'Souza., 2015). HNSCC represents the third most common cause of cancer death worldwide. Platinum based regimens represent cornerstone in its treatment (Galbiattiet al., 2013). Cisplatin (cis-diammine dichloroplatinum (II), CDDP) is an inorganic platinum-based chemotherapeutic agent that is widely used in treatment of various solid malignancies as head and neck, lung, testis, ovarian, and bladder cancers (Aparecida et al., 2012). The use of cisplatin is frequently limited by significant side effects including bone marrow suppression, peripheral neuropathy, ototoxicity, anaphylaxis and nephrotoxicity with the latter representing the main dose limiting one (Aparecida et al., 2012). Acute kidney injury (AKI), distal renal tubular acidosis, renal concentrating defect, transient proteinuria, hyperuricemia, Fanconi-like syndrome, hypomagnesemia, hypocalcemia, renal salt wasting, erythropoietin deficiency, thrombotic microangiopathy, and chronic renal failure are among the renal side effects of cisplatin (Miller et al., 2010).Renal function deterioration is seen in 25% to 35% of patients treated with a single dose of cisplatin (Miller et al., 2010).Cisplatin-induced injury to renal epithelial cells results in the production of various inflammatory factors, including TNF-α. Cisplatin also increases ROS production, which leads to the activation of apoptosis and necrosis pathways (Miller et al., 2010). Pentoxifylline (PTX), a nonspecific phosphodiesterase inhibitor, was first considered in the treatment of peripheral vascular diseases (Nasiri-Toosi et al., 2013). PTX has anti-inflammatory effects as it down regulates several pro-inflammatory cytokines, including tumor necrosis factor alpha (TNF-α) and interleukin-1 (IL-1) and IL-6 (Mostafa-Hedeab et al., 2022). In addition, PTX has gained considerable interest as a reactive oxygen species (ROS) scavenger, and several studies show its potential antioxidant effects (Zhang et al., 2016). Several studies evaluate the renoprotective effects of PTX against drug-induced nephrotoxicity (Ramesh and Reeves, 2002; Kasap et al., 2013;Nasiri-Toosi et al.,2013; Panahi-Shokouh etal., 2020; Alorabi et al., 2022).

Criteria for eligibility:
Criteria:
Inclusion criteria: 1. Patient aged 18 years or more with head and neck cancer who will receive cisplatin for the first time. 2. Baseline estimated glomerular filtration rate (eGFR) ≥ 59 ml/min/1.73 m2. 3. Eastern Cooperative Oncology Group performance status (ECOG) < 2. 4. Patients with normal organic function as defined for the following criteria: - Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 times the upper normal limit of the local laboratory ; - Total serum bilirubin ≤ 2.0 x ULN-LL; - Absolute neutrophil count ≥ 1,500 / mm3; - Platelet count ≥ 100,000 / mm3; - Hemoglobin ≥ 8.0 g / dl; - Serum creatinine ≤ 1.5 x ULN-LL Exclusion criteria: 1. Pregnant or nursing women, or females intending pregnancy were all prohibited 2. Patients with concurrent other malignancy or history of other malignancy treated within the past 3 years. 3. Baseline estimated glomerular filtration rate (eGFR) < 59 ml/min/1.73 m2. 4. Alanine aminotransferase (ALT) > 3× times ULN. 5. Eastern Cooperative Oncology Group performance status (ECOG) ≥2. 6. Patients have Diabetes mellitus. 7. Patients have current participation in other protocols with experimental drugs. 8. Patients with no ability to ingest food orally. 9. Pentoxifylline hypersensitivity. 10. Use of other nephrotoxic drugs as aminoglycosides, non-steroidal anti-inflammatory drugs and contrast media.

Gender: All

Minimum age: 18 Years

Maximum age: 75 Years

Healthy volunteers: No

Start date: December 2022

Completion date: June 2023

Lead sponsor:
Agency: Tanta University
Agency class: Other

Source: Tanta University

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05640817